Single dose of psilocybin for depression shows promising results in UK's first publicly funded randomized trial
medicalxpress - The first randomized controlled trial in the U.K. has found that a single dose of psilocybin, the active compound found in "magic mushrooms," produced significant improvements in depression compared with a placebo. This is the first publicly funded random…
AI Summary: A publicly funded randomized trial in the UK found that a single dose of psilocybin, delivered in a clinical setting, produced promising improvements for people with treatment-resistant major depressive disorder. The results suggest psychedelic-assisted therapy could be a viable addition to standard care—pending larger trials and careful safety monitoring—challenging old assumptions about one-and-done fixes.
FDA approves first drug for full range of narcolepsy symptoms
medicalxpress - The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults. Orzeyful marks the first medication approved for the full range of symptoms associated with narcolepsy type 1 and is the first approved…
AI Summary: The FDA has approved a medication that treats the full range of narcolepsy symptoms, including excessive daytime sleepiness and cataplexy, marking the first such comprehensive option for patients with narcolepsy type 1. Clinicians now have a single, regulated choice to address multiple debilitating symptoms rather than juggling piecemeal therapies.